Cited 51 times in
Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정일 | - |
dc.date.accessioned | 2023-08-09T02:35:42Z | - |
dc.date.available | 2023-08-09T02:35:42Z | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195660 | - |
dc.description.abstract | Background/aims: This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB). Methods: We investigated 2,061 Korean treatment-naïve patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071). The difference of HCC development among risk groups (low, intermediate, and high) categorized by risk score was also investigated. Results: The cumulative incidence rates of HCC at 5 years were 11.2% and 8.9% in the testing and validation cohorts, respectively. HCC-Risk Estimating Score in CHB patients Under Entecavir (HCC-RESCUE) is formulated as (age+15×gender [female=0 / male=1]+23×cirrhosis [absence=0 / presence=1]). The AUROCs at 1 year, 3 years, and 5 years were 0.82, 0.81, and 0.81, respectively, in the validation cohort. A significant difference of HCC development in each risk group was determined by the 5-year HCC risk score in the validation cohort (low risk group, 2.1%; intermediate risk group, 9.3%; high risk group, 41.2%, p<0.001). Conclusions: The study presents a new risk score model with a good ability to predict HCC development and determine high risk patients for HCC development consisting of readily available clinical factors in treatment-naïve CHB patients receiving entecavir. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antiviral Agents / therapeutic use* | - |
dc.subject.MESH | Area Under Curve | - |
dc.subject.MESH | Carcinoma, Hepatocellular / diagnosis* | - |
dc.subject.MESH | Carcinoma, Hepatocellular / epidemiology | - |
dc.subject.MESH | Carcinoma, Hepatocellular / etiology | - |
dc.subject.MESH | DNA, Viral / blood | - |
dc.subject.MESH | DNA, Viral / genetics | - |
dc.subject.MESH | DNA, Viral / metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Guanine / analogs & derivatives* | - |
dc.subject.MESH | Guanine / therapeutic use | - |
dc.subject.MESH | Hepatitis B e Antigens / blood | - |
dc.subject.MESH | Hepatitis B virus / isolation & purification | - |
dc.subject.MESH | Hepatitis B, Chronic / complications | - |
dc.subject.MESH | Hepatitis B, Chronic / drug therapy* | - |
dc.subject.MESH | Hepatitis B, Chronic / virology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Liver Neoplasms / diagnosis* | - |
dc.subject.MESH | Liver Neoplasms / epidemiology | - |
dc.subject.MESH | Liver Neoplasms / etiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | ROC Curve | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.title | Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Won Sohn | - |
dc.contributor.googleauthor | Ju-Yeon Cho | - |
dc.contributor.googleauthor | Ji Hoon Kim | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Hyung Joon Kim | - |
dc.contributor.googleauthor | Min-Ah Woo | - |
dc.contributor.googleauthor | Sin-Ho Jung | - |
dc.contributor.googleauthor | Yong-Han Paik | - |
dc.identifier.doi | 10.3350/cmh.2016.0086 | - |
dc.contributor.localId | A03122 | - |
dc.relation.journalcode | J00557 | - |
dc.identifier.eissn | 2287-285X | - |
dc.identifier.pmid | 28506056 | - |
dc.subject.keyword | Antiviral drugs | - |
dc.subject.keyword | Assessment, Risk | - |
dc.subject.keyword | Chronic hepatitis B | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.contributor.alternativeName | Lee, Jung Il | - |
dc.contributor.affiliatedAuthor | 이정일 | - |
dc.citation.volume | 23 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 170 | - |
dc.citation.endPage | 178 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, Vol.23(2) : 170-178, 2017-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.